EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition

Cristina Gómez iD, Zerin Alimajstorovic, Nantia Othonos, Denise V Winter, Sarah White, Gareth G Lavery, Jeremy W Tomlinson, Alexandra J Sinclair, Alex Odermatt iD

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16251 ↗

At a glance

Journal article in British Journal of Pharmacology, 2024. Written by Cristina Gómez and 8 co-authors. Institution: Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Major MEDLINE topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1, Glucocorticoids. Cited 4 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council, Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose 11β‐Hydroxysteroid dehydrogenase‐1 (11β‐HSD1) catalyses the oxoreduction of cortisone to cortisol, amplifying levels of active glucocorticoids. It is a pharmaceutical target in metabolic disease and cognitive impairments. 11β‐HSD1 also converts some 7oxo‐steroids to their 7β‐hydroxy forms. A recent study in mice described the ratio of tauroursodeoxycholic acid (TUDCA)/tauro‐7oxolithocholic acid (T7oxoLCA) as a biomarker for decreased 11β‐HSD1 activity. The present study evaluates the equivalent bile acid ratio of glycoursodeoxycholic acid (GUDCA)/glyco‐7oxolithocholic acid (G7oxoLCA) as a biomarker for pharmacological 11β‐HSD1 inhibition in humans and compares it with the currently applied urinary (5α‐tetrahydrocortisol + tetrahydrocortisol)/tetrahydrocortisone ((5αTHF + THF)/THE) ratio. Experimental Approach Bile acid profiles were analysed by ultra‐HPLC tandem‐MS in blood samples from two independent, double‐blind placebo‐controlled clinical studies of the orally administered selective 11β‐HSD1 inhibitor AZD4017. The blood GUDCA/G7oxoLCA ratio was compared with the urinary tetrahydro‐glucocorticoid ratio for ability to detect 11β‐HSD1 inhibition. Key Results No significant alterations were observed in bile acid profiles following 11β‐HSD1 inhibition by AZD4017, except for an increase of the secondary bile acid G7oxoLCA. The enzyme product/substrate ratio GUDCA/G7oxoLCA was found to be more reliable to detect 11β‐HSD1 inhibition than the absolute G7oxoLCA concentration in both cohorts. Comparison of the blood GUDCA/G7oxoLCA ratio with the urinary (5αTHF + THF)/THE ratio revealed that both successfully detect 11β‐HSD1 inhibition. Conclusions and Implications 11β‐HSD1 inhibition does not cause major alterations in bile acid homeostasis. The GUDCA/G7oxoLCA ratio represents the first blood biomarker of pharmacological 11β‐HSD1 inhibition and may replace or complement the urinary (5αTHF + THF)/THE ratio biomarker.

Subjects

MeSH terms (MEDLINE)

11-beta-Hydroxysteroid Dehydrogenase Type 1GlucocorticoidsAnimalsHumansMiceBile Acids and SaltsBiomarkersHydrocortisoneTetrahydrocortisol

Author keywords

11β-hydroxysteroid dehydrogenaseLC-MSbile acidbiomarkerdiseaseglucocorticoidinhibitor

Substances

11-beta-Hydroxysteroid Dehydrogenase Type 1Bile Acids and SaltsBiomarkersGlucocorticoidsHydrocortisoneTetrahydrocortisol

Authors and institutions

  • Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Metabolic Neurology, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
  • Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.
  • Department for Biosciences, Nottingham Trent University, Nottingham, UK.
  • Department of Neurology, University Hospitals Birmingham, Birmingham, UK.

ORCID profiles: Cristina Gómez, Alex Odermatt

Funding

  • Medical Research Council
  • Swiss National Science Foundation
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Cite

APA

Gómez, C., Alimajstorovic, Z., Othonos, N., Winter, D. V., White, S., Lavery, G. G., Tomlinson, J. W., Sinclair, A. J., & Odermatt, A. (2024). Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition. British Journal of Pharmacology. https://doi.org/10.1111/bph.16251

Vancouver

Gómez C, Alimajstorovic Z, Othonos N, Winter DV, White S, Lavery GG, et al. Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition. British Journal of Pharmacology. 2024. doi:10.1111/bph.16251

BibTeX
@article{Gmez2024,
  author = {Gómez, Cristina and Alimajstorovic, Zerin and Othonos, Nantia and Winter, Denise V and White, Sarah and Lavery, Gareth G and Tomlinson, Jeremy W and Sinclair, Alexandra J and Odermatt, Alex},
  title = {Identification of a human blood biomarker of pharmacological 11β‐hydroxysteroid dehydrogenase 1 inhibition},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16251}
}
Start for free →